Place oral film directly onto the tongue where it will disintegrate and can then be swallowed with saliva without the need for water or other liquids. Oral film: 25 mg, 50 mg, 75 mg, 100 mg of sildenafil ( 3) Administration of SILDENAFIL ORAL FILM to patients using nitric oxide donors, such as organic nitrates or organic nitrites in any form. SILDENAFIL ORAL FILM was shown to potentiate the hypotensive effect of nitrates. Known hypersensitivity to sildenafil or any component of oral film. Administration with guanylate cyclase (GC) stimulators, such as riociguat. Patients should not use SILDENAFIL ORAL FILM if sexual activity is inadvisable due to cardiovascular status. Patients should seek emergency treatment if an erection lasts >4 hours. Use SILDENAFIL ORAL FILM with caution in patients predisposed to priapism.

Before Using

Patients should stop SILDENAFIL ORAL FILM and seek medical care if a sudden loss of vision occurs in one or both eyes, which could be a sign of non-arteritic anterior ischemic optic neuropathy (NAION). SILDENAFIL ORAL FILM should be used with caution, and only when the anticipated benefits outweigh the risks, in patients with a history of NAION. Patients with a “crowded” optic disc may also be at an increased risk of NAION.

Product	Dosage	Quantity + Bonus	Price
Viagra Generic	50mg	20 Pills	40.52€ 38.59€
Viagra Generic	200mg	20 Pills	61.69€ 58.75€
Kamagra Soft Tabs	100mg	180 + 8 Pills	425.45€ 405.19€
Kamagra	100mg	360 + 6 Pills	839.95€ 799.95€
Viagra Generic	150mg	10 Pills	36.73€ 34.98€
Kamagra Oral Jelly	100mg	110 + 9 Sachets	334.87€ 318.92€
Viagra Generic	50mg	30 + 4 Pills	54.26€ 51.68€
Kamagra Polo	100mg	120 + 6 Pills	327.15€ 311.57€
Viagra Generic	100mg	10 Pills	28.91€ 27.53€
Kamagra	100mg	60 + 4 Pills	201.34€ 191.75€
Kamagra Polo	100mg	20 Pills	83.56€ 79.58€
Kamagra Polo	100mg	272 + 12 Pills	622.94€ 593.28€
Viagra Generic	100mg	120 + 6 Pills	149.50€ 142.38€

Patients should stop SILDENAFIL ORAL FILM and seek prompt medical attention in the event of sudden decrease or loss of hearing.

Sildenafil oral strips provide a non-invasive way to treat ED.
They avoid swallowing pills, which some patients find difficult.
Strips are often manufactured with pleasant flavors to enhance appeal.
The medication’s effect can be influenced by food intake.
Alcohol consumption may reduce effectiveness or increase side effects.
Sildenafil strips should be used as prescribed and not mixed with other ED drugs.
These strips are designed for quick absorption in the oral mucosa.
Overuse or misuse can lead to adverse health effects.
Proper dosing helps minimize risks of prolonged erections or priapism.
Sildenafil strips do not cure ED but help manage symptoms.
They may be used in combination with psychological or lifestyle interventions.
Always check expiration dates before using sildenafil strips.

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. Decreased blood pressure, syncope, and prolonged erection may occur at higher sildenafil exposures. In patients taking strong CYP inhibitors such as ritonavir, sildenafil exposure is increased. Decrease in sildenafil citrates SILDENAFIL ORAL FILM dosage is recommended. Most common adverse reactions (≥ 2%) include headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness and rash. To report SUSPECTED ADVERSE REACTIONS, contact YARAL Pharma Inc at 1-866-218-9009 or FDA at 1-800-FDA-1088 or SILDENAFIL ORAL FILM can potentiate the hypotensive effects of nitrates, alpha blockers, and antihypertensives.

Parameter	Description	Typical Values	Notes
Absorption Time	Time to reach peak plasma levels	15-30 minutes	Faster than tablets
Peak Plasma Concentration	Max concentration after dose	120-250 ng/mL	Varies with dose
Half-life	Time for plasma levels to reduce by half	3-5 hours	Limits dosing frequency
Bioavailability	Percentage of dose reaching systemic circulation	Approx. 80%	Enhanced via mucosal absorption

( 4.1, 5.5, 7.1, 7.2, 7.3, 12.2) With concomitant use of alpha blockers, initiate SILDENAFIL ORAL FILM at 25 mg dose. Ritonavir: Do not exceed a maximum single dose of 25 mg in a 48- hour period. Erythromycin or strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, saquinavir): Consider a starting dose of 25 mg. ( 2.2, 7.4) See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

11. Sildenafil Oral Film Description

Therefore, treatments for erectile dysfunction, including SILDENAFIL ORAL FILM should not be used in men for whom sexual activity is inadvisable because of their underlying cardiovascular status. The following groups of patients were not included in clinical safety and efficacy trials for sildenafil, and therefore, until further information is available, SILDENAFIL ORAL FILM is not recommended for use in the following groups: Patients who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months Patients with resting hypotension (BP <90/50 mmHg) or hypertension (BP >170/110 mmHg) Patients with cardiac failure or coronary artery disease causing unstable angina. Patients with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure can be sensitive to the actions of vasodilators, including SILDENAFIL ORAL FILM. As with other PDE5 inhibitors, SILDENAFIL ORAL FILM has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers. In healthy subjects aged 18 to 45 years, SILDENAFIL ORAL FILM 100 mg resulted in mean maximal decreases relative to placebo of 6 mmHg systolic and 3 mmHg diastolic.

So Happy!

In healthy subjects aged 65 years and older, SILDENAFIL ORAL FILM 100 mg resulted in mean maximal decreases relative to placebo of 14 mmHg systolic and 8 mmHg diastolic [see Clinical Pharmacology (12.2)]. Prior to prescribing SILDENAFIL ORAL FILM, carefully consider whether patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects, especially in combination with sexual activity. Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported infrequently since market approval of sildenafil. In the event of an erection that persists longer than 4 hours, instruct the patient to seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result.

Is S-FILM safe to use in patients with diabetes?

Use SILDENAFIL ORAL FILM with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie’s disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia). Advise patients to stop use of all phosphodiesterase type 5 (PDE5) inhibitors, including SILDENAFIL ORAL FILM and seek medical attention in the event of a sudden loss of vision in one or both eyes. Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision including permanent loss of vision, that has been reported rarely post-marketing in temporal association with the use of all PDE5 inhibitors. Based on published literature, the annual incidence of NAION is 2.5-11.8 cases per 100,000 in males aged 50 years and older. An observational case-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period. SILDENAFIL ORAL FILM is indicated for the treatment of erectile dysfunction. For most patients, the recommended dosage is 50 mg orally administered on the tongue, taken as needed, approximately 1 hour before sexual activity. The maximum recommended dosing frequency is once per day. Based on effectiveness and tolerability the dosage may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg, not to exceed once per day. For administration instructions, see Dosage and Administration (2.4).

Sildenafil strips are an alternative to traditional pill forms.
The strips dissolve quickly, eliminating need for water to swallow.
They are convenient for on-the-go use and discreet consumption.
Possible side effects include headache, flushing, and dizziness.
Sildenafil strips should be used approximately one hour before activity.
Not suitable for individuals with certain health conditions; consult a doctor.
They are typically used in men aged 18 and above.
The medication works by increasing blood flow to the penis.
Sildenafil strips can be part of a broader erectile dysfunction treatment plan.
Side effects may vary depending on individual health status.
Erectile response may improve with proper use and dosing.
They are available through licensed pharmacies and online sources.

Concomitant use of nitrates in any form is contraindicated [see Contraindications (4.1), Drug Interactions (7.1) and Clinical Pharmacology (12.2)]. Initiate SILDENAFIL ORAL FILM at 25 mg orally in patients on concomitant therapy with an alpha-blocker. Patients should be stable on alpha-blocker therapy prior to initiating SILDENAFIL ORAL FILM [seeWarningsand Precautions (5.5), Drug Interactions(7.2), and Clinical Pharmacology(12.2)]. The maximum recommended dose and dosing frequency is 25 mg orally taken once within a 48-hour period in ritonavir-treated patients. Concomitant administration of ritonavir increased the blood levels of sildenafil by 11-fold [seeWarnings andPrecautions (5.6), Drug Interactions (7.4), and Clinical Pharmacology (12.3)]. The recommended starting dosage is 25 mg orally, in patients taking strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or saquinavir) or erythromycin. Clinical data have shown that co-administration with saquinavir or erythromycin increased blood levels of sildenafil by about 3-fold [seeDrug Interactions (7.4) and Clinical Pharmacology (12.3)]. The recommended starting dosage is 25 mg orally in patients greater than 65 years of age [see Use in Specific Populations(8.5)]. The recommended starting dosage is 25 mg orally, in patients with severe renal impairment (creatinine clearance less than 30 mL/minute). The recommended starting dosage is 50 mg, in patients with mild (creatinine clearance 50 to 80 mL/min) and moderate (creatinine clearance 30 to 49 mL/min) renal impairment [see Use in Specific Populations(8.6) and Clinical Pharmacology (12.3)].

Mark Milligan

Decrease in sildenafil citrates SILDENAFIL ORAL FILM dosage is recommended. Most common adverse reactions (≥ 2%) include headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness and rash. To report SUSPECTED ADVERSE REACTIONS, contact YARAL Pharma Inc at 1-866-218-9009 or FDA at 1-800-FDA-1088 or SILDENAFIL ORAL FILM can potentiate the hypotensive effects of nitrates, alpha blockers, and antihypertensives. ( 4.1, 5.5, 7.1, 7.2, 7.3, 12.2) With concomitant use of alpha blockers, initiate SILDENAFIL ORAL FILM at 25 mg dose. Ritonavir: Do not exceed a maximum single dose of 25 mg in a 48- hour period.

Can I take S-FILM as often as I want?

Erythromycin or strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, saquinavir): Consider a starting dose of 25 mg. ( 2.2, 7.4) See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. SILDENAFIL ORAL FILM is indicated for the treatment of erectile dysfunction. For most patients, the recommended dosage is 50 mg orally administered on the tongue, taken as needed, approximately 1 hour before sexual activity. The maximum recommended dosing frequency is once per day.

5.8 Effects on Bleeding

Based on effectiveness and tolerability the dosage may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg, not to exceed once per day. For administration instructions, see Dosage and Administration (2.4). Concomitant use of nitrates in any form is contraindicated [see Contraindications (4.1), Drug Interactions (7.1) and Clinical Pharmacology (12.2)]. Initiate SILDENAFIL ORAL FILM at 25 mg orally in patients on concomitant therapy with an alpha-blocker. Patients should be stable on alpha-blocker therapy prior to initiating SILDENAFIL ORAL FILM [seeWarningsand Precautions (5.5), Drug Interactions(7.2), and Clinical Pharmacology(12.2)]. The recommended starting dosage is 25 mg orally in patients with any degree of hepatic impairment. In volunteers with mild and moderate degrees of hepatic impairment (Child-Pugh Class A and B), sildenafil clearance was reduced, resulting in higher plasma exposure of sildenafil (47% for Cmax and 85% for AUC), and the pharmacokinetics of sildenafil in patients with severe hepatic impairment (Child-Pugh Class C) have not been studied [see Use in Specific Populations (8.7)and Clinical Pharmacology (12.3)]. 25 mg sildenafil, opaque light blue, thin, flexible oral film imprinted with identification code S 25 50 mg sildenafil, opaque light blue, thin, flexible oral film imprinted with identification code S 50 75 mg sildenafil, opaque light blue, thin, flexible oral film imprinted with identification code S 75 100 mg sildenafil, opaque light blue, thin, flexible oral film imprinted with identification code S 100 Consistent with its known effects on the nitric oxide/cGMP pathway [see Clinical Pharmacology (12.1,12.2)] , SILDENAFIL ORAL FILM potentiates the hypotensive effects of nitrates, and its administration to patients who are using nitric oxide donors such as organic nitrates or organic nitrites in any form either regularly and/or intermittently is therefore contraindicated. After patients have taken SILDENAFIL ORAL FILM it is unknown when nitrates, if necessary, can be safely administered. Although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration, it is unknown whether nitrates can be safely co-administered at this time point [seeDosage and Administration (2.2), Drug Interactions (7.1), and Clinical Pharmacology (12.2)].

Side Effect	Frequency	Severity	Management	Notes
Headache	Common	Mild	Analgesics, hydration	Usually transient
Flushing	Common	Mild	Cooling measures	May subside quickly
Nasal Congestion	Less common	Mild	Decongestants if needed	Temporary sensation
Dizziness	Occasional	Variable	Stable position, hydration	Caution in motor activities
Visual disturbances	Rare	Moderate	Seek medical advice	Usually reversible

SILDENAFIL ORAL FILM is contraindicated in patients with a known hypersensitivity to sildenafil or any SILDENAFIL ORAL FILM component. Hypersensitivity reactions, sildenafil white including rash and urticaria, have been reported [see Adverse Reactions (6.1)]. There is a potential for cardiac risk of sexual activity in patients with preexisting cardiovascular disease. Therefore, treatments for erectile dysfunction, including SILDENAFIL ORAL FILM should not be used in men for whom sexual activity is inadvisable because of their underlying cardiovascular status. The following groups of patients were not included in clinical safety and efficacy trials for sildenafil, and therefore, until further information is available, SILDENAFIL ORAL FILM is not recommended for use in the following groups: Patients who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months Patients with resting hypotension (BP <90/50 mmHg) or hypertension (BP >170/110 mmHg) Patients with cardiac failure or coronary artery disease causing unstable angina.

Frequently asked questions

Q: Will V-ORAL STRIPS 100mg increase sexual desire?

Patients should not use SILDENAFIL ORAL FILM if sexual activity is inadvisable due to cardiovascular status. Patients should seek emergency treatment if an erection lasts >4 hours. Use SILDENAFIL ORAL FILM with caution in patients predisposed to priapism. Patients should stop SILDENAFIL ORAL FILM and seek medical care if a sudden loss of vision occurs in one or both eyes, which could be a sign of non-arteritic anterior ischemic optic neuropathy (NAION). SILDENAFIL ORAL FILM should be used with caution, and only when the anticipated benefits outweigh the risks, in patients with a history of NAION.

5.9 Counseling Patients About Sexually Transmitted Diseases

Patients with a “crowded” optic disc may also be at an increased risk of NAION. Patients should stop SILDENAFIL ORAL FILM and seek prompt medical attention in the event of sudden decrease or loss of hearing. Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. Decreased blood pressure, syncope, and prolonged erection may occur at higher sildenafil exposures. In patients taking strong CYP inhibitors such as ritonavir, sildenafil exposure is increased. Patients with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure can be sensitive to the actions of vasodilators, including SILDENAFIL ORAL FILM. As with other PDE5 inhibitors, SILDENAFIL ORAL FILM has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers. In healthy subjects aged 18 to 45 years, SILDENAFIL ORAL FILM 100 mg resulted in mean maximal decreases relative to placebo of 6 mmHg systolic and 3 mmHg diastolic. In healthy subjects aged 65 years and older, SILDENAFIL ORAL FILM 100 mg resulted in mean maximal decreases relative to placebo of 14 mmHg systolic and 8 mmHg diastolic [see Clinical Pharmacology (12.2)]. Prior to prescribing SILDENAFIL ORAL FILM, carefully consider whether patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects, especially in combination with sexual activity. Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported infrequently since market approval of sildenafil. In the event of an erection that persists longer than 4 hours, instruct the patient to seek immediate medical assistance.

FAQ's on S-FILM Orally Disintegrating Strip

The results suggest an approximate 2-fold increase in the risk of NAION, with a risk estimate of 2.15 (95% CI 1.06, 4.34). If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result. Use SILDENAFIL ORAL FILM with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie’s disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia).

Plain Language Summary

The maximum recommended dose and dosing frequency is 25 mg orally taken once within a 48-hour period in ritonavir-treated patients. Concomitant administration of ritonavir increased the blood levels of sildenafil by 11-fold [seeWarnings andPrecautions (5.6), Drug Interactions (7.4), and Clinical Pharmacology (12.3)]. The recommended starting dosage is 25 mg orally, in patients taking strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or saquinavir) or erythromycin. Clinical data have shown that co-administration with saquinavir or erythromycin increased blood levels of sildenafil by about 3-fold [seeDrug Interactions (7.4) and Clinical Pharmacology (12.3)]. The recommended starting dosage is 25 mg orally in patients greater than 65 years of age [see Use in Specific Populations(8.5)].

Professional resources

The recommended starting dosage is 25 mg orally, in patients with severe renal impairment (creatinine clearance less than 30 mL/minute). The recommended starting dosage is 50 mg, in patients with mild (creatinine clearance 50 to 80 mL/min) and moderate (creatinine clearance 30 to 49 mL/min) renal impairment [see Use in Specific Populations(8.6) and Clinical Pharmacology (12.3)]. The recommended starting dosage is 25 mg orally in patients with any degree of hepatic impairment. In volunteers with mild and moderate degrees of hepatic impairment (Child-Pugh Class A and B), sildenafil clearance was reduced, resulting in higher plasma exposure of sildenafil (47% for Cmax and 85% for AUC), and the pharmacokinetics of sildenafil in patients with severe hepatic impairment (Child-Pugh Class C) have not been studied [see Use in Specific Populations (8.7)and Clinical Pharmacology (12.3)]. 25 mg sildenafil, opaque light blue, thin, flexible oral film imprinted with identification code S 25 50 mg sildenafil, opaque light blue, thin, flexible oral film imprinted with identification code S 50 75 mg sildenafil, opaque light blue, thin, flexible oral film imprinted with identification code S 75 100 mg sildenafil, opaque light blue, thin, flexible oral film imprinted with identification code S 100 Consistent with its known effects on the nitric oxide/cGMP pathway [see Clinical Pharmacology (12.1,12.2)] , SILDENAFIL ORAL FILM potentiates the hypotensive effects of nitrates, and its administration to patients who are using nitric oxide donors such as organic nitrates or organic nitrites in any form either regularly and/or intermittently is therefore contraindicated.

What is the average Sildenafil strips price?

After patients have taken SILDENAFIL ORAL FILM it is unknown when nitrates, if necessary, can be safely administered. Although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration, it is unknown whether nitrates can be safely co-administered at this time point [seeDosage and Administration (2.2), Drug Interactions (7.1), and Clinical Pharmacology (12.2)]. SILDENAFIL ORAL FILM is contraindicated in patients with a known hypersensitivity to sildenafil or any SILDENAFIL ORAL FILM component. Hypersensitivity reactions, sildenafil white including rash and urticaria, have been reported [see Adverse Reactions (6.1)]. There is a potential for cardiac risk of sexual activity in patients with preexisting cardiovascular disease. Advise patients to stop use of all phosphodiesterase type 5 (PDE5) inhibitors, including SILDENAFIL ORAL FILM and seek medical attention in the event of a sudden loss of vision in one or both eyes. Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision including permanent loss of vision, that has been reported rarely post-marketing in temporal association with the use of all PDE5 inhibitors. Based on published literature, the annual incidence of NAION is 2.5-11.8 cases per 100,000 in males aged 50 years and older. An observational case-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period. The results suggest an approximate 2-fold increase in the risk of NAION, with a risk estimate of 2.15 (95% CI 1.06, 4.34).

Sildenafil oral strips are a fast-acting form of erectile dysfunction medication.
They are administered orally, dissolving quickly on the tongue for rapid effect.
Sildenafil strips are often flavored to improve the user experience.
They contain the same active ingredient as traditional sildenafil tablets.
These strips are designed for people seeking discreet medication options.
Onset of action for sildenafil strips can be within 15-30 minutes.
Proper storage of sildenafil strips involves keeping them in a cool, dry place.
Dosage strength varies, typically available in 25mg, 50mg, and 100mg.
Using sildenafil strips without medical consultation is not recommended.
They may interact with other medications like nitrates or alpha-blockers.
Sildenafil oral strips are approved for the treatment of erectile dysfunction.
Users should follow prescribed dosages for safety and effectiveness.

Sildenafil Orally Strip 50mg